MADRIGAL PHARMACEUTICALS,INC. (NASDAQ:MDGL) Files An 8-K Results of Operations and Financial Condition
Item2.02 Results of Operations and Financial Condition.
On April3, 2017 Madrigal Pharmaceuticals,Inc. issued a press
release announcing its results for its fourth quarter and fiscal
year ended December31, 2016. A copy of the press release is
furnished herewith as Exhibit99.1 to this Current Report on
Form8-K and is incorporated herein by reference.
The information in this Current Report on Form8-K and the
accompanying Exhibit99.1 shall not be deemed filed for purposes
of Section18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act) or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the
Exchange Act, regardless of any general incorporation language in
such filing, unless expressly incorporated by reference in such
filing.
Item9.01 Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit Number |
|
Description |
|
99.1 |
Press Release of Madrigal Pharmaceuticals,Inc. Dated |
About MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL)
Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL) Recent Trading Information
MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL) closed its last trading session down -0.05 at 15.40 with 8,829 shares trading hands.
